Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells $23,632.85 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insider David Bharucha sold 12,245 shares of Milestone Pharmaceuticals stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $1.93, for a total value of $23,632.85. Following the completion of the transaction, the insider directly owned 99,848 shares of the company’s stock, valued at approximately $192,706.64. This trade represents a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

David Bharucha also recently made the following trade(s):

• On Monday, December 15th, David Bharucha sold 58,007 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.32, for a total value of $134,576.24.

Milestone Pharmaceuticals Trading Up 1.1%

NASDAQ MIST opened at $1.91 on Friday. The stock has a market capitalization of $162.67 million, a P/E ratio of -2.33 and a beta of 0.44. The business has a 50 day simple moving average of $2.22 and a 200 day simple moving average of $1.97. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24. Milestone Pharmaceuticals Inc. has a one year low of $0.63 and a one year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. Research analysts expect that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several large investors have recently added to or reduced their stakes in MIST. Simplify Asset Management Inc. increased its holdings in Milestone Pharmaceuticals by 186.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after purchasing an additional 1,842,974 shares in the last quarter. Valeo Financial Advisors LLC boosted its position in shares of Milestone Pharmaceuticals by 553.5% during the second quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock valued at $254,000 after buying an additional 110,699 shares during the last quarter. Aptus Capital Advisors LLC bought a new stake in Milestone Pharmaceuticals during the third quarter worth $420,000. Propel Bio Management LLC raised its position in Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after buying an additional 3,333,333 shares during the last quarter. Finally, Raymond James Financial Inc. lifted its stake in Milestone Pharmaceuticals by 30.1% during the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors own 86.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on MIST shares. Wells Fargo & Company lifted their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, Zacks Research raised Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.